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E-mail address: ran.brosh@weizmann.ac.il (R. BrosThe p53 tumor suppressor coordinates a multitude of cellular and organismal processes and exerts
its activities mainly by activation of gene transcription. Here we describe the transcriptional activa-
tion of ectodysplasin A2 receptor (EDA2R) by p53 in a variety of cell types and tissues. We demon-
strate that treatment of cancer cells with the ligand EDA-A2, known to speciﬁcally activate
EDA2R, results in p53-dependent cell death. Moreover, we show that EDA2R is transactivated by
p53 during chemotherapy-induced hair-loss, although its presence is not necessary for this process.
These data shed new light on the role of EDA2R in exerting p53 function.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The transcription factor p53 is a pivotal tumor suppressor that
integrates a wide variety of stress signalling pathways and is in-
volved in numerous processes, including cell-cycle, apoptosis, dif-
ferentiation, metabolism, senescence, etc. p53 exerts its activity
primarily through transcriptional activation of target genes, few
dozens of which were identiﬁed during the thirty years of p53 re-
search [1]. Utilizing RNA interference to knockdown p53 in human
embryonic ﬁbroblasts, followed by global expression analysis, we
identiﬁed ectodysplasin A2 receptor (EDA2R) as a potential tran-
scriptional target of p53 in these cells.
EDA2R, also known as XEDAR (X-linked Ectodermal Dysplasia
Receptor), encodes a transmembranal receptor that belongs to
the tumor necrosis factor (TNF)-receptor superfamily [2]. EDA2R,
as well as its paralog, EDAR, bind the ectodysplasin ligands EDA-
A2 and EDA-A1, respectively; which are two alternatively spliced
forms of the EDA gene [2]. Mutations in the EDA gene are associ-chemical Societies. Published by E
a; HHFs, human hair follicles;
rpin RNA; WT, wild-type; KO,
vot 76100, Israel. Fax: +972 8
h).ated with the X-linked form of Hypohidrotic Ectodermal Dysplasia
(HED), a disease typically characterized by abnormal hair, teeth
and sweat glands. Likewise, the autosomal form of HED may stem
from mutations in the EDAR gene [3]. Although both EDAR and its
ligand EDA are associated with HED, there are currently no reports
of mutations in EDA2R in patients with this disease. Nevertheless,
substantial data portray EDA2R as an apoptosis-inducing death
receptor and implicate it in the regulation of ectodermal functions.
For example, EDA2R was demonstrated to induce caspase-depen-
dent apoptosis upon EDA-A2 treatment [4,5]. Moreover, in chick-
ens, EDA2R is speciﬁcally expressed in placodes, the epithelial
regions that give rise to feathers, and expression of a dominant-
negative EDA2R suppresses feather development [6]; while in hu-
mans, a speciﬁc single nucleotide polymorphism in EDA2R coding
region is associated with Androgenetic Alopecia (also known as
male pattern baldness) [7]. In contrast to the reported roles of
EDA2R in apoptosis, and its association with the growth of hair
or feathers, knockout of EDA2R in mice was reported to have no
phenotypic effect [8]. Interestingly, Tanikawa et al. had recently
identiﬁed EDA2R as a p53 target gene that mediates anoikis, and
suggested that EDA2R is a tumor suppressor that limits colorectal
cancer progression [9].
Taken together, the aforementioned data led us to hypothesize
that the transactivation of EDA2R might mediate p53-dependentlsevier B.V. All rights reserved.
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lowing chemotherapy, a process known as chemotherapy-induced
alopecia (CIA), was shown to be strictly dependent on p53 [10], and
to involve apoptosis of hair follicles in response to the chemother-
apy-induced DNA-damage [11]. Therefore, we speculated that
EDA2R might mediate p53-dependent CIA. Hair-loss is one of the
most common and traumatic adverse effects of chemotherapy
[12], and currently it is virtually untreatable. Hence, studying the
mechanisms that underlie CIA is of high importance, and may facil-
itate the development of novel therapeutic strategies.
2. Materials and methods
2.1. Cell culture
Immortalized WI-38 and IMR90 cells were cultured in MEM
supplemented with 10% FCS, 1 mM sodium pyruvate, 2 mM L-glu-
tamine and antibiotics. Mouse embryonic ﬁbroblasts (MEFs) were
derived from wild-type p53 (WT-p53) and p53 knockout (p53-
KO) sibling embryos, and maintained in DMEM supplemented with
10% FCS and antibiotics. U2OS and H1299 cell lines were cultured
in DMEM and RPMI, respectively, with 10% FCS and antibiotics.
2.2. Plasmids and infections
Small hairpin RNAs (shRNAs) targeting p53 (sh-p53), or mouse
NOXA (sh-con) were stably expressed using pRetroSuper and were
described in [13]. Mutant p53R248Q was generated by site-directed
mutagenesis of pWZL-WT-p53 vector. Retroviral infection and the
immortalization of WI-38 cells were described in [14].
2.3. EDA-A2 treatment and cell survival analysis
sh-p53 and sh-con U2OS cells were treated with EDA-A2 (R&D
systems) at a concentration of 50 ng/mL for 24 h. Cells were
stained with Crystal Violet and washed with PBS. Crystal Violet
was extracted with acetic acid and quantiﬁed using a spectropho-
tometer at 590 nm. Cell death was estimated by Propidium Iodide
(PI) exclusion: cells were trypsinized, stained with PI (50 ng/mL)
and analyzed using a ﬂow cytometer.
2.4. RNA preparation and QRT-PCR
RNAwas extractedwith TRI-Reagent (Molecular Research Center
Inc.) and reverse transcribed using Bio-RT (Biolab) and random
hexamers. Quantitative real-time PCR (QRT–PCR) was performed
using Platinum SYBR Green qPCR SuperMix (Invitrogen). Human
and mouse mRNA levels were normalized to the level of GAPDH
and HPRT, respectively, of the corresponding sample. PCR reactions
were performed in duplicates and error bars in charts represent
the corresponding standard deviations. For analysis of mRNA
expression in vivo, tissues from threemicewere collectedper exper-
imental category, and error bars in charts represent S.E.M. (standard
error of mean). Primer sequences are listed in Supplementary
Table 1.
2.5. Western blotting
Western blot analysis was performed as described in Ref. [14]
with the following antibodies: a-p53 pAb H-47, a-p21 sc-377
(Santa Cruz), and a-GAPDH MAB374 (Chemicon).
2.6. Mice and induction of alopecia in vivo
C57BL/6 p53-KO mice were kindly provided by Dr. G. Lozano
(University of Texas, MD Anderson Cancer Center). EDA2R-KOmicewere kindly provided by Genentech and were described by Newton
et al. [8]. Induction of alopecia was performed as described in Ref.
[15]. Brieﬂy, back sections of 6–8 weeks old C57BL/6 anesthetized
mice were depilated using 1:1 mixture of beeswax and gum rosin
(Sigma). Nine days later, mice were injected i.p. with 150 mg/kg
cyclophosphamide (CYP). Hair loss was monitored visually approx-
imately one week after CYP injection.3. Results
3.1. EDA2R is transcriptionally activated by p53 is human and mouse
cells
As mentioned above, stable expression of a p53-speciﬁc shRNA
(sh-p53) in WI-38 human embryonic ﬁbroblasts led to a pro-
nounced decrease in the expression of EDA2R compared to control
shRNA-expressing cells (sh-con). To support the notion that EDA2R
is transcriptionally activated by p53 in normal human cells, we
treated sh-p53 and sh-con WI-38 cells with Nutlin-3a, a small-
molecule that stabilizes p53 protein by inhibiting its Mdm2-
dependent degradation [16], and measured the expression of
EDA2R, as well as p21 (CDKN1A) as a positive control for p53 acti-
vation. As depicted in Fig. 1A and B, in sh-con cells, Nutlin-3a en-
hanced p53 protein level and led to the transactivation of EDA2R
and p21. This effect was completely abrogated in sh-p53 cells.
The expression of EDA2R was further analyzed in the human fetal
IMR90 primary lung ﬁbroblasts. Indeed, p53 inactivation, either
by shRNA or by expression of a dominant-negative DNA-contact
mutant p53 (Fig. 1C), strongly attenuated the expression of EDA2R
(Fig. 1D). p53 was capable of transcriptionally inducing EDA2R also
in human cancer cells. Speciﬁcally, when the p53-null H1299 lung
adenocarcinoma cells were transfected with either WT-p53 or the
conformational mutant p53R249S, a robust WT-p53-dependent
induction of EDA2R transcription was observed. Similarly, treat-
ment of WT-p53-expresssing HCT-116 colorectal carcinoma cells
and their p53-KO counterparts with Doxorubicin, a widely-used
chemotherapeutic agent, resulted in p53-dependent EDA2R induc-
tion (Supplementary Fig. 1). Furthermore, EDA2Rwas validated as a
p53 target gene in additional cell lines, including U2OS osteosar-
coma (Fig. 2A) and MCF7 breast adenocarcinoma (data not shown).
Finally, MEFs, originating from either WT-p53 or p53-KO mice, dis-
played clear p53-dependent expression and Nutlin-3a-induced
upregulation of EDA2R (Fig. 1E). In conclusion, EDA2R transcription
is directly activated by p53 in a large variety of normal and cancer-
ous cell types of human and mouse origin.
In agreement with Tanikawa et al. [9], we also observed that
two adjacent p53 consensus binding sites in the ﬁrst intron of
EDA2R mediate its transcriptional activation by p53. As shown in
Supplementary Fig. 2 and described in detail in the supplementary
ﬁgure legend, chromatin-immunoprecipitation analysis revealed
p53 binding to the region containing these two consensus binding
sites. Luciferase reporter studies demonstrated that these sites are
functional and only mutations in both sites could abrogate the
p53-dependent activation of the reporter.
3.2. EDA-A2 treatment results in p53-dependent cell death
Chang et al. previously demonstrated that EDA2R can induce
caspase-dependent apoptosis upon EDA-A2 treatment [5]. We
therefore reasoned that p53-dependent induction of EDA2R may
increase the sensitivity of cells to EDA-A2. To test this hypothesis
we focused on WT-p53-expressing U2OS osteosarcoma cells and
their sh-p53-expressing counterparts, which express lower levels
of EDA2R (Fig. 2A). Treatment of these cells with recombinant
EDA-A2 resulted in a p53-dependent and EDA-A2-induced cell
Fig. 1. EDA2R is transactivated by p53 in human ﬁbroblasts. (A and B) sh-p53 and sh-conWI-38 cells were treated with Nutlin-3a (10 lM, 24 h). Protein levels were measured
by Western blotting (A). mRNA levels of p21 and EDA2R were measured by QRT-PCR (B). (C and D) sh-con, sh-p53 and mutant p53R248Q-expressing IMR90 cells were assayed
for p53 and p21 protein levels by Western blotting (C) and mRNA levels of p21 and EDA2R by QRT-PCR (D). (E) Mouse embryonic ﬁbroblasts, originating from either a WT-p53
or a p53-KO mouse, were treated with Nutlin-3a (10 lM, 24 h) and analyzed for p21 and EDA2R expression by QRT-PCR.
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centage of dead cells (Fig. 2). Similarly, EDA-A2 treatment of H1299
p53-null cells, which were ﬁrst transfected with either WT-p53 or
mutant p53, resulted in induction of apoptosis only in WT-p53-
transfected cells (Supplementary Fig. 1E).
3.3. EDA2R is induced by p53 in chemotherapy-treated mouse skin and
in human hair follicles
Asmentioned above, the ectodysplasin family of receptors and li-
gands are implicated in the control of hair growth and in pathologies
associated with abnormal hair growth. We therefore hypothesized
that the induction of EDA2R by p53 might mediate the effect of
p53 on hair growth and hair loss. Importantly, p53 was reported to
be essential for CIA (hair-loss), a process involving p53-dependent
apoptosis of hair follicles [17]. We therefore tested if EDA2R is in-
ducedbyp53during theprocess of CIA. To this end,weapplied a spe-
ciﬁc experimental protocol [15] to chemically induce alopecia in
WT-p53 and p53-KO mice. According to this protocol, the mouse
dorsal fur is ﬁrst depilated in order to synchronize hair growth. After
nine days, when hair follicles reach the chemotherapy-sensitive
stage, cyclophosphamide (CYP), a chemotherapeutic drug, is in-
jected. Approximately one week later, the dorsal fur should be shed
in CYP-treatedmice. As shown in Fig. 3A, whenWT-p53 and p53-KO
female mice were treated according to this protocol, they displayed
complete p53-dependent loss of their dorsal fur. i.e., p53-KO femalemice did not shed their hair at all, while WT-p53 females displayed
complete hair loss in the previously-depilated area. Surprisingly, in
male mice treated under the same conditions, p53 had only a mild
effect, slightly delaying the kinetics of hair loss. To the best of our
knowledge, this is the ﬁrst report of such clear gender-speciﬁc
dependence on p53 in the context of CIA.
Importantly, EDA2R expression was signiﬁcantly induced in a
p53-dependent manner in the mice back skin approximately
2 days after cyclophosphamide injection (Fig. 3B). Interestingly,
the expression of p21, which mediates cell-cycle arrest [18], was
repressed. These results support the suggested role of EDA2R in
mediating apoptosis of hair follicles. Of note, the p53-dependent
induction of EDA2R in CYP-treated mice was not conﬁned to the
skin, and was also evident in the lungs (Fig. 3C) and liver (data
not shown). Moreover, EDA2R was also transcriptionally activated
by p53 following ionizing irradiation in several mouse tissues (data
not shown).
Next, to test whether EDA2R is induced also in human hair fol-
licles (HHFs) following chemotherapy, we analyzed samples of
in vitro cultivated HHFs that were treated with the active deriva-
tive of cyclophosphamide, 4-hydro-peroxy-cyclophosphamide (4-
HC) [19]. Analysis of mRNA extracted from 20 pooled HHFs from
two different individuals demonstrated that EDA2R and p21 were
upregulated following 4-HC treatment (Fig. 3D).
Finally, we tested whether EDA2R is required for CIA in mice.
We obtained EDA2R-KO mice, which were previously generated
Fig. 2. EDA-A2 treatment results in p53-dependent cell death. (A–C) sh-con and sh-
p53 U2OS cells were treated with EDA-A2. A. mRNA levels were measured by QRT-
PCR in non-treated cells. (B) Estimation of cell amount by Crystal Violet. EDA-A2-
treated and non-treated (NT) cells were stained with Crystal Violet and washed.
Crystal Violet was then extracted with acetic acid and its concentration was
quantiﬁed at OD 590 nm and the values were normalized to the sh-con non-treated
sample. C. Analysis of cell death by Propidium Iodide exclusion. Cells were
trypsinized and stained with Propidium Iodide. The percentage of positive cells,
representing dead cells, was measured by ﬂow cytometry.
Fig. 3. EDA2R is upregulated following chemotherapy in a p53-dependent manner.
(A–C) WT-p53 (WT) and p53-KO (KO) mice were depilated and treated with
cyclophosphamide (150 mg/kg) 9 days later. (A) Representative images of treated
male and female mice 8 days after cyclophosphamide treatment. (B and C)
Expression of p21 and EDA2R in dorsal skin (B) or lungs (C) 2 days after injection
of Cyclophosphamide (CYP) or water (Con). (D) Expression of p21 and EDA2R in
in vitro cultivated human hair follicles derived from two different donors, 2 days
after treatment with the active derivative of cyclophosphamide (4-HC) or control
treatment (Con).
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their WT littermates [8]. We applied the same CIA protocol
described above to test whether EDA2R-KO mice, similarly to
p53-KO female mice, will display attenuated CIA. Interestingly, de-
spite the p53-dependent induction of EDA2R in the dorsal skin of
CYP-treated mice, our experiments did not demonstrate any signif-
icant attenuation of CIA, as EDA2R-KO mice displayed the same de-
gree of hair-loss as their WT controls following cyclophosphamide
administration (data not shown).
4. Discussion
The combination of previously published data and the results
described above lead to the conclusion that EDA2R is a bona ﬁde
p53 target gene, which is activated in a wide variety of cell types
and tissues of both human and mouse origin, and following a vari-
ety of p53-activating signals. Importantly, p53 transactivates
EDA2R transcription in cancer cells and sensitizes them to EDA-
A2-induced death, suggesting a therapeutic potential for this
ligand. EDA2R is upregulated in vivo in a p53-dependent manner
in the mouse skin, as well as in other tissues, following chemother-
apy and radiotherapy. A similar phenomenon is apparent in human
hair follicles. Since p53 activity is essential for CIA in female mice
([10] and Fig. 3), it is reasonable to assume that one or more p53
target genes are required for this process. Nevertheless, our results
indicate that although EDA2R is induced by p53 during CIA, it is not
necessary for the induction of hair loss, perhaps due to compensa-
tion by other pro-apoptotic p53 targets or even by p53-indepen-
dent mechanisms. Supporting the ﬁrst possibility; the p53 target
gene FAS, which, similarly to EDA2R, encodes a member of the
TNF-receptor superfamily; was reported to be activated during
CIA, and its deletion decreases the levels of apoptotic markers in
regressing hair follicles, but do not abrogate CIA [20]. Deletion of
both FAS and EDA2Rmay potentially exert a greater attenuating ef-
fect on CIA than abrogation of each of them alone. Alternatively, itis also possible that p53 promotes apoptosis in hair follicles by
trans-activating additional targets, or even by non-transcriptional
activities [21]. Moreover, we demonstrate that in male mice, lack
of p53 does not abrogate CIA, while in females, p53 is essential
for this process. This clearly indicates a compensation for p53 loss
in the context of CIA in males. In fact, some developmental defects
associated with p53 deﬁciency, such as exencephaly, display low
penetrance and appear most of the times in female embryos, indi-
cating that in most cases, and particularly in males, p53 deﬁciency
R. Brosh et al. / FEBS Letters 584 (2010) 2473–2477 2477is compensated, likely by p53 family members p63 and p73 [22].
Thus, it is possible that in the absence of EDA2R, p53 cannot initiate
CIA, and this is compensated not by a different p53 target, but by a
different pathway which is independent of p53. Finally, it is also
possible that although EDA2R is elevated during CIA, this receptor
does not initiate any signalling due to low concentration or ab-
sence of its ligand EDA-A2. Moreover, it was demonstrated
in vitro that while high concentrations of EDA-A2 induce cell death
[4], treatment with low concentrations can induce cell survival;
and this induction is mediated by EDA2R-dependent activation of
NFkB [23]. The antagonistic effects of EDA2R may thus result in a
more complex scenario in vivo.
In sum, this study broadens our understanding of p53 function,
and implicates p53 as a regulator of ectodysplasin signalling. Addi-
tionally, our data suggest a role for EDA2R in mediating p53-depen-
dent cell death and offer a platform for further studies on the role
of the p53 and EDA2R in CIA.
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